SCHEMBL4019490

SCHEMBL4019490

Nc1nc2cc(CON3C(=O)CCC3=O)ccc2o1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.42
▸ LMNA P02545 2/20 0.42
▸ CYP1A2 P05177 1/20 0.42
▸ THRB P10828 1/20 0.42
▸ ALOX15 P16050 1/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ PIK3CA P42336 7/20 0.37
▸ PIK3CD O00329 2/20 0.37
▸ PIK3CB P42338 2/20 0.37
▸ PIK3CG P48736 2/20 0.37
▸ MTOR P42345 6/20 0.35
▸ TP53 P04637 2/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ NFKB1 P19838 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ NFKB2 Q00653 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4025674 0.76 MAPT (0.53) MAPTLMNACYP1A2THRBALOX15
SCHEMBL13765046 0.75 MAPT (0.51) MAPTLMNACYP1A2THRBALOX15
SCHEMBL13486453 0.73 MEN1 (0.44) MAPTTP53KDM4EMEN1ALDH1A1
SCHEMBL14074957 0.71 MAPT (0.47) MAPTLMNACYP1A2THRBALOX15
SCHEMBL4016091 0.70 MAPT (0.56) MAPTLMNACYP1A2THRBALOX15
SCHEMBL4019751 0.70 MAPT (0.61) MAPTLMNACYP1A2THRBALOX15
SCHEMBL240344 0.70 RAB9A (0.63) MAPTLMNACYP1A2THRBALOX15
Hydrochloric Acid SCHEMBL6601598 0.68 MAOB (0.42) THRB
SCHEMBL20748550 0.67 MAPT (0.53) MAPTLMNACYP1A2THRBALOX15
SCHEMBL18405092 0.67 MAPT (0.53) MAPTLMNACYP1A2THRBALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7563877-B2 Processes for the preparation of 0-(2-aminobenzo[d]oxazol-5-yl)methyl hydroxylamine for the synthesis of 6,11-bicyclic erythromycin derivative EDP-182 ENANTA PHARMACEUTICALS, INC. (US) 2009-07-21 — — US claimed
US-20070207972-A1 Processes for the preparation of 0-(2-aminobenzo[d]oxazol-5-yl)methyl hydroxylamine for the synthesis of 6,11-bicyclic erythromycin derivative EDP-182 ENANTA PHARMACEUTICALS, INC. 2007-09-06 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070207972-A1 Processes for the preparation of 0-(2-aminobenzo[d]oxazol-5-yl)methyl hydroxylamine for the synthesis of 6,11-bicyclic erythromycin derivative EDP-182 DHPS, TET1, TET2 MAPT 4438/4885LMNA 1591/4885CYP1A2 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback